

# Yingkai Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6711445/publications.pdf>

Version: 2024-02-01

10  
papers

208  
citations

1307594

7  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

271  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). <i>Lancet Neurology</i> , The, 2020, 19, 970-971.	10.2	85
2	Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China. <i>Frontiers in Neurology</i> , 2018, 9, 77.	2.4	34
3	Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients. <i>Experimental Neurology</i> , 2019, 312, 43-50.	4.1	23
4	Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis. <i>Journal of Neuroimmunology</i> , 2020, 345, 577279.	2.3	17
5	Knowledge and perceptions of the COVID-19 pandemic among patients with myasthenia gravis. <i>Muscle and Nerve</i> , 2021, 63, 357-364.	2.2	13
6	Normative dataset for plasma cytokines in healthy human adults. <i>Data in Brief</i> , 2021, 35, 106857.	1.0	11
7	The clinical need for clustered AChR cell-based assay testing of seronegative MG. <i>Journal of Neuroimmunology</i> , 2022, 367, 577850.	2.3	9
8	Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients. <i>Clinical Immunology</i> , 2020, 218, 108492.	3.2	7
9	Imbalance of the two main circulating dendritic cell subsets in patients with myasthenia gravis. <i>Clinical Immunology</i> , 2019, 205, 130-137.	3.2	5
10	Cellular changes in eculizumab early responders with generalized myasthenia gravis. <i>Clinical Immunology</i> , 2021, 231, 108830.	3.2	4